Potential of gene therapy for brain tumors

Human Molecular Genetics

Volumn 10, Issue 7, 2001, Pages 777-787

  Lam, Paula Y P ^a,b   Breakefield, Xandra O ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; FLUCYTOSINE; GANCICLOVIR; PRODRUG; RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR ANTIGEN; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ANGIOGENESIS; APOPTOSIS; BRAIN TUMOR; CELL DIVISION; CELL INVASION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DRUG ACTIVATION; GENE TARGETING; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RETROVIRUS; REVIEW; TRANSGENE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; HERPES; SIMPLEXVIRUS; UNIDENTIFIED RETROVIRUS;

EID: 0035057752     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/10.7.777     Document Type: Review

References (164)

1. Primary central nervous system tumors in adults
2. Clinical aspects of brain tumor
3. '...those left behind.' Biology and oncology of invasive glioma cells
4. The molecular genetics of CNS tumors
5. Molecular pathways in the formation of gliomas
6. Prodrug-activating enzymes in cancer gene therapy
7. Drug selection of MDR1-transduced hematopoietic cells ex vivo increases transgene expression and chemoresistance in reconstituted bone marrow in mice
8. Modification of the radiation response by the administration of exogenous genes
9. Radiation to control gene expression
10. Targeting adenovirus
11. Gene therapy for gliomas: Molecular targets, adenoviral vectors and oncolytic adenoviruses
12. Methods for gene delivery to neural tissue
13. Genetically modified rat 9L gliosarcoma cells facilitate detection of infiltrating tumor cells in a rat model of brain neoplasms
14. Changes in proliferating cell nucleus antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory
15. Selective expression of interleukin-10 gene within glioblastoma multiforme
16. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma
17. Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice
18. Transferrin receptor in normal and neoplastic brain tissue: Implications for brain-tumor immunotherapy
19. Transferrin receptor on endothelium of brain capillaries
20. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors
21. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells
22. Recombinant human adenovirus: Targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium
23. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma
24. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models
25. In vivo protein transduction: Delivery of a biologically active protein into the mouse
26. Evaluation of VP22 spread in tissue culture
27. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22
28. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
29. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta and epsilon with very different potencies and have unique mechanisms of action
30. Curability of tumors bearing herpes thymidine kinase genes transferred by retrovirus vectors
31. An experimental model of retrovirus gene therapy for malignant brain tumors
32. In vivo gene transfer with retroviral producer cells for treatment of experimental brain tumors
33. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
34. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
35. Gap junctions promote the bystander effect of herpes simplex virus thymidine kinase in vivo
36. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
37. Oxidative metabolism of cyclophosphamide: Identification of the hepatic monooxygenase catalysts of drug activation
38. Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene
39. Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine
40. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies
41. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene and radiotherapy
42. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat
43. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene
44. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies
45. Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas
46. Genetic instability leads to loss of both p53 alleles in a human glioblastoma
47. Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line
48. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
49. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of experimental intracranial human malignant glioma
50. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
51. Increase of BCNU sensitivity by wt-p53 gene therapy in glioblastoma lines depends on the administration schedule
52. Chemosensitivity of human malignant glioma: Modulation by p53 gene transfer
53. Adenovirus-mediated transfer of bax with caspase-8 controlled by myelin basic protein promoter exerts an enhanced cytotoxic effect in gliomas
54. Adenovirus-mediated gene transfer of dominant negative Ha-Ras inhibits proliferation of primary meningioma cells
55. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells
56. Herpes simplex virus amplications as tools to analyze pro-apoptotic gene function in primary neurons
57. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo
58. Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration
59. Human glioma immunobiology in vitro: Implications for immunogene therapy
60. Steering anti-cancer drugs away from the TRAIL
61. Progress in antiangiogenic gene therapy of cancer
62. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells
63. Vascular endothelial growth factor (VEGF) in astrocytic gliomas - A prognostic factor?
64. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
65. Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2
66. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
67. Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas
68. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
69. Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene delivery
70. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for targeted radiotherapy
71. A lentiviral vector expression a fusogenic glycoprotein for cancer gene therapy
72. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas
73. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
74. Connexin 43-enhanced suicide gene therapy using herpes viral vectors
75. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy
76. Diffuse brain invasion of glioma cells requires beta 1 integrins
77. Expression of human alpha(1, 3)fucosyl-transferase antisense sequences inhibits selectin-mediated adhesion and liver metastasis of colon carcinoma cells
78. Immunobiology of the blood-brain barrier
79. The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-beta, T-c apoptosis and the immune privilege of the brain
80. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
81. Design of a novel small peptide targeted against a tumor-specific receptor
82. Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen
83. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2
84. Mononuclear cell infiltration in central portions of human astrocytomas
85. Helper virus-free Herpes simplex virus type 1 amplicon vectors for granulocyte-macrophage colony-stimulating factor-enhanced vaccination therapy for experimental glioma
86. Prolongation of survival of mice with glioma treated with semi-allogeneic fibroblasts secreting interleukin-2
87. Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats
88. Characterization of a spontaneous murine astrocytomas and abrogation of its tumorigenicity by cytokine secretion
89. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors
90. From the cover: Engineered herpes simplex virus expression IL-12 in the treatment of experimental murine brain tumors
91. Gene therapy in the CNS
92. Viral and nonviral gene delivery vectors for cancer gene therapy
93. Development and characterization of cationic liposomes conjugated with HSJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer
94. Noninvasive gene targeting to the brain
95. Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy
96. Gene therapy using HVJ-liposomes: The best of both worlds?
97. Preclinical development strategies for novel gene therapeutic products
98. Hybrid vector designs to control the delivery, fate and expression of transgenes
99. Viral vectors for gene therapy: The art of turning infectious agents into vehicles of therapeutics
100. Gene therapy - Promises, problems and prospects
101. Current status of viral gene therapy for brain tumors
102. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors
103. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity
104. Experimental therapy of human glioma by means of a genetically engineered virus mutant
105. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
106. Retrovirus therapy of tumors with activated Ras pathway
107. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
108. Glioma/glioblastoma-specific adenoviral gene expression using the nestin gene regulator
109. Chronic brain inflammation and persistent HSV1-TK expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
110. Viral induced demyelination
111. Tumor-specific killer cells in paraneoplastic cerebellar degeneration
112. Introduction of a foreign gene (lacZ of E coli) into rat neostriatal neurons using herpes simplex virus mutants: A light and electron microscopic study
113. Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line
114. In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein
115. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase
116. Adenovirus vectors as transcomplementing templates for the production of replication defective retroviral vectors
117. Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein Barr virus hybrid amplicons
118. Characterization of replication-competent retroviruses from nonhuman primates with virus-induced T-cell lymphomas and observations regarding the mechanism of oncogenesis
119. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme
120. Herpes virus vectors for gene therapy in the nervous system
121. Herpes simplex virus as a gene-delivery vector for the central nervous system
122. Gene delivery to rat enteric neurons using herpes simplex virus-based vectors
123. Molecular circuitry regulating herpes simplex virus type 1 latency in neurons
124. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction
125. Immunocytochemical characterization of long-term persistent immune activation in human brain after herpes simplex encephalitis
126. ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro
127. Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma
128. HSV.com: Maneuvering the internetworks of viral neuropathogenesis and evasion of the host defense
129. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
130. Toxicity and neuronal infection of a HSV-1 ICP34.5 mutant in nude mice
131. Selective in vitro replication of herpes simplex virus type 1 (HSV-1) ICP34.5 null mutants in primary human CNS tumors - Evaluation of a potentially effective clinical therapy
132. Herpes vector-mediated delivery of thymidine kinase gene to disseminated CNS tumors
133. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas
134. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy
135. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial
136. Adenovirus vectors for gene delivery
137. Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes
138. Expression and interactions of human adenovirus oncoproteins
139. Tumor-specific, replication-competent adenovirus vectors overexpression the adenovirus death protein
140. Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity
141. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach
142. Extended release of adenovirus from polymer microspheres: Potential use in gene therapy for brain tumors
143. Pretreatment with protease is a useful experimental strategy for enhancing adenovirus-mediated cancer gene therapy
144. Antitumor activity and reporter gene transfer into rat brain tumors inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase
145. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells
146. Transduction of glioma cells using a high-titer retroviral vector system and their subsequent migration in brain tumors
147. Endothelial cell implantation and survival within experimental gliomas
148. Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas
149. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas
150. Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?
151. Mammalian neural stem cells
152. Plasticity and stem cells in the vertebrate nervous system
153. Gene therapy of experimental brain tumors using neural progenitor cells
154. Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model
155. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-produced cells
156. Angiogenesis in cancer and other diseases
157. Selective intra-arterial gene delivery into a canine meningioma
158. Delivery of herpes virus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption
159. Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms
160. The identification of novel therapeutic targets for the treatment of malignant brain tumors
161. Toward a molecular classification of the gliomas: Histopathology, molecular genetics and expression profiling
162. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas
163. Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expression